Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation zaps skin cancer without surgery

NCT ID NCT02131805

Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new device that delivers targeted radiation to early-stage basal and squamous cell skin cancers. Thirty-six people aged 60 and older received treatment, and researchers tracked how well the cancer was controlled, cosmetic results, and quality of life. The goal was to see if this approach is a safe and effective alternative to surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Electronic Skin Surface Brachytherapy (radiation delivered via a device)
What this could lead to
If successful, this could offer a non-surgical, convenient treatment option for early-stage skin cancers with good cosmetic results.
What could go wrong
This is a small pilot study with only 36 participants, so results may not apply to everyone. Side effects from radiation, such as skin irritation, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

36 people

The number who actually took part.

Started

May 2014

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women ≥ 60 years old with estimated life expectancy of ≥ 5 years * Histopathologic diagnosis of basal or squamous cell carcinoma * Clinical stage T1N0M0 (by AJCC 2010 criteria) °Basal cell carcinoma with morpheaform, sclerosing, mixed, infiltrative or micronodular features must be ≤1 cm * Low risk pathologic features (by AJCC 2010 criteria) * Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 (Appendix C) * Able and willing to complete the Skindex16 and Skin Cancer Index (must be able to speak English) * Ability to provide informed consent Exclusion Criteria: * BCC/SCC that was previously treated (ie, recurrent BCC/SCC) * BCC/SCC in region adjacent to or overlapping with region of prior radiotherapy * BCC/SCC on irregular surface (ie, target area not flat) * BCC/SCC adjacent to or overlapping with burn or scar * BCC/SCC in area prone to trauma (including, but not limited to the skin overlying the tibia, dorsum of hands and elbow) * BCC/SCC in area with compromised lymphatic drainage or vascular supply * BCC/SCC within 3 cm of another treated or untreated BCC/SCC * Inflammatory process in target area * Collagen vascular disease (lupus, scleroderma, rheumatoid arthritis) * Diabetes that is poorly controlled * Genetic disorder predisposing patient to skin cancers or radiation sensitivity (basal cell nevus syndrome, xeroderma pigmentosum, ataxia telangiectasia mutans) * Receipt of treatment with another investigational device or drug * Receipt of drug that will affect biologic response to radiation (radiosensitizer or radioprotector) * High likelihood of protocol non-compliance (in opinion of investigator)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Basal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

basal cell carcinoma skin basal cell carcinoma squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cutaneous basal cell Squamous cell carcinoma

Contacts and locations

Locations

  • Boca Raton Regional Hospital

    Boca Raton, Florida, 33486, United States

  • Memorial Sloan Kettering Basking Ridge (Consent only)

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Bergen (Consent only)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack (Consent only)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (Consent only)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Consent only)

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester (All Protocol Activities)

    Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.